DDInter105 DDInter142
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020.
Avapritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Avapritinib {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Avapritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Avapritinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Avapritinib may lead to a major life threatening interaction when taken with Golimumab
Avapritinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Avapritinib may lead to a major life threatening interaction when taken with Flurbiprofen